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Background
Rapid drug desensitization (RDD) is widely used to
re-introduce medications that have caused an IgE-
mediated hypersensitivity in allergic patients. However,
RDD protocols are largely based on empiric experience
and few in vitro models have explored the rationale guid-
ing the rate at which the dose should be increased, what
the starting dose should be and how the time elapsed
between doses affect the effectiveness of desensitization.
This study addresses these issues in a new humanized in
vitro model of rapid desensitization.
Methods
Bone marrow-derived mast cells (BMMCs) from trans-
genic Balb/c mice expressing the human high affinity IgE
receptor alpha chain (hFcRI) were sensitized with human
serum containing IgE against dust mites. Sensitized
BMMCs were challenged with Dermatophagoides ptero-
nyssinus administered at once (activation) or through a
step-wise progressive increase in concentration (desensiti-
zation). The influence of the concentration fold-increase
per step, of the starting concentration and of the time
elapsed between steps on the inhibition of mediator
release (-hexosaminidase) induced by desensitization was
assessed.
Results
Inhibition of -hexosaminidase release correlated with the
fold-increase per step, the starting concentration and the
time elapsed between steps. A two-fold increase per step
protocol induced 81% inhibition compared to 51%
(p=0.001) and 19% (p=0.003) for four-fold and ten-fold
increase per step protocols. Maximal inhibition was
reached with a starting concentration below the activation
threshold (80%) and a progressive reduction in inhibition
was observed with starting concentrations above that
threshold. One-minute intervals between steps induced a
small degree of inhibition (15%) that was maximal with
10-minute intervals (81%) (p<0.001).
Conclusion
This in vitro humanized mast cell/IgE-mediated desensiti-
zation model will allow evaluation of drug hypersensitivity
patients and provide the basis for adjusting the fold-
increase per step, the starting concentration and the time
between steps necessary for safe rapid drug desensitiza-
tion. These three factors independently influence the inhi-
bition of mediators release and should be taken into
account in all RDD protocols.
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